Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Dechra Pharmaceuticals makes bolt-on acquisition

It is paying £4.4mln or 2.4-times revenues for Caledonian Holdings
Dechra Pharmaceuticals makes bolt-on acquisition
The UK group is buying a New Zealand supplier to vets specialising in horses

Dechra Pharmaceuticals PLC (LON:DPH) has made a small bolt-on acquisition.

It is paying £4.4mln or 2.4-times revenues, for Caledonian Holdings, a New Zealand supplier to vets specialising in horses.

The deal will establish Dechra as a leading equine pharmaceutical supplier in both Australia and New Zealand, the company said.

"We are pleased to have acquired the trade and assets of Caledonian which will be integrated into our existing Australian and New Zealand businesses. This will enable Dechra to leverage its position in the ANZ equine market," said chief executive Ian Page.

 

View full DPH profile View Profile

Dechra Pharmaceutical Timeline

Related Articles

scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use